Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

AstraZeneca reports ‘highly effective’ vaccine

The drugmaker AstraZeneca announced on Monday that an early analysis of some of its late-stage clinical trials, conducted in the United Kingdom and Brazil, showed...

| By Kelley Gipson

Dr. Carine Boustany promoted at Boehringer Ingelheim

Dr. Carine Boustany has been named Global Head, Development Science and Head, Development Site U.S. at Boehringer Ingelheim, beginning January 1, 2021. Dr. Boustany sits on...

| By Kelley Gipson

Halda to move to Science Park in New Haven

Halda Therapeutics, a Branford-based biotech company, plans to move to New Haven after signing a lease for a 9,800 square-foot lab and office space in in...

| By Kelley Gipson

Yale expands rollout of SalivaDirect virus test

Yale University has added 13 states to the national rollout of its much-anticipated SalivaDirect COVID-19 test. Yale has now approved more than 30 independent labs...

| By Kelley Gipson

Rallybio begins research on treatment for bleeding

A New Haven-based biopharmaceutical company has launched development efforts for a drug to treat a rare, life-threatening disorder that can cause uncontrolled bleeding in fetuses...

| By Kelley Gipson

Moderna reports promising results re COVID vaccine

The Massachusetts-based company Moderna has reported promising preliminary results from its coronavirus vaccine trial. Coming just a week after similar news from Pfizer and BioNTech,...

| By Kelley Gipson

Connecticut helped develop COVID-19 vaccine

If the Pfizer-involved COVID-19 vaccine is successful in beating the spread of the pandemic that has gripped the nation for nearly 10 months, it will...

| By Kelley Gipson

NanoViricides engages Calvert Labs for safety studies

NanoViricides has engaged Calvert Labs, a contract research organization, for performing the safety pharmacology studies of its clinical drug candidate for the treatment of COVID-19....

| By Kelley Gipson

CytoVeris names Harvard’s Dr. Michael Fenn to SAB

CytoVeris has appointed Dr. Michael Fenn, Ph.D., Harvard University, as the newest member of its Scientific Advisory Board (SAB). Dr. Fenn serves as the Director...